Femasys Inc. — Q3 2026 Earnings Summary

Femasys Inc. announced a $30 million private placement in mid-August 2026 to fund U.S. commercial team expansion and the FemBloc pivotal trial. For the quarter ended September 30, 2026, U.S. sales rose slightly to $347,039, while total sales declined 44.5% to $404,597 due to timing of international distributor orders. The company reported a net loss of $4,564,815 for the quarter and $8,187,810 for the nine-month period, with cash and cash equivalents reaching approximately $23.9 million by September 30.